Skip to content
2000
Volume 15, Issue 7
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Anticoagulant therapy is widely used for the treatment and prophylaxis of deep vein thrombosis and coronary syndromes. Until now, drugs such as unfractionated heparin and low molecular weight heparins need to be administered parenterally. Parenteral administration results in lower patient compliance compared to oral therapy and for this reason, the focus of various research groups is to develop an oral heparin formulation which is as effective as the parenteral formulation, easy to use and non-toxic. In the last few years, some new oral anticoagulants like Rivaroxaban (Xarelto®), Apixaban (Eliquis®) and Dabigatranetexilat (Pradaxa®) have reached the market, but their use is limited to certain indications. Therefore, the development of oral formulations with well-established anti-coagulant drugs is still relevant and in demand. In this paper, we reviewed strategies that have been developed so far to achieve an adequate anticoagulant effect using oral formulations of unfractionated and low molecular weight heparins.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/1389201015666140915151649
2014-07-01
2025-07-04
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/1389201015666140915151649
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test